HYBRID EVENT: Join us in person in London, UK or attend virtually from anywhere.
Juvenile Rheumatoid Arthritis (JRA), also known as Juvenile Idiopathic Arthritis (JIA), is a chronic autoimmune inflammatory disorder that primarily affects children under the age of 16, leading to persistent joint pain, swelling, and stiffness. This debilitating condition encompasses a heterogeneous group of arthritic diseases, with symptoms ranging from mild joint discomfort to severe systemic involvement. The etiology of JRA remains elusive, with genetic predisposition and environmental factors believed to contribute to its onset. The hallmark feature is inflammation of the synovium, the membrane lining the joints, which can eventually lead to joint damage and deformities. JRA is classified into several subtypes based on clinical manifestations, including oligoarthritis, polyarthritis, systemic arthritis, enthesitis-related arthritis, and psoriatic arthritis, each presenting distinct challenges in diagnosis and management. The unpredictable nature of JRA poses significant physical and emotional challenges for affected children and their families, often impacting their daily activities, school attendance, and overall quality of life. Early diagnosis and intervention are crucial to prevent long-term joint damage, and treatment approaches typically involve a combination of nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), biologics, and physical therapy. The multidisciplinary care of JRA patients involves rheumatologists, Paediatricians, physical therapists, and other healthcare professionals working collaboratively to tailor treatment plans to individual needs. Despite significant advances in understanding and managing JRA, ongoing research efforts strive to unravel its complexities, improve therapeutic options, and ultimately enhance the prognosis and well-being of children grappling with this challenging autoimmune condition.
